TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30373740
Drug: Curcumin (2000-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (2000-mg doses 8 times over 4 days)
Study: 27829388
Drug: Maternal Oral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal Oral Screening (MOS) tool
Study: 27829388
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Impact Profile (OHIP-14)
Study: 24797294
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment (40 mg/kg of amoxicillin‐clavulanate per day for 7 days)
Study: 22039291
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) containing 0.5 mg NE and 0.035 mg EE
Study: 22039291
Drug: OC plus
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC plus telaprevir (750 mg every 8 hours)
Study: 20561115
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene education (ST)
Study: 12040477
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg rhGM-CSF solution (group A, n = 18)
Study: 12040477
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (group B, n = 23)
Study: 2548554
Drug: Cilazapril 0.5
Normalized name: cilazapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 0.5 mg
Study: 2548554
Drug: Cilazapril 1
Normalized name: cilazapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1 mg
Study: 2548554
Drug: Cilazapril 0.5
Normalized name: cilazapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 0.5 mg daily (multiple dose phase)
Study: 2548554
Drug: Cilazapril 1
Normalized name: cilazapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1 mg daily (multiple dose phase)
Study: 31228593
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) of antagonist muscles plus single ES session on injected muscles
Study: 16960930
Drug: Tacrolimus 3
Normalized name: Tacrolimus 300 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 3 mg once daily
Study: 16960930
Drug: Mizoribine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine 50 mg three times daily
Study: 8372768
Drug: MR arthrography
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR arthrography with 40-50 ml of a 1:100 solution of gadopentetate dimeglumine in saline
Study: 3534730
Drug: Cefoperazone 1
Normalized name: cefoperazone 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 1 g IV every 8 hours for 5 days
Study: 3534730
Drug: Cotrimoxazole 800
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole 800 mg sulfamethoxazole and 160 mg trimethoprim every 12 hours for 5 days
Study: 30634046
Drug: Design systems
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Design systems that collect data for treatment personalization
Study: 29424799
Drug: AS04-HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-HPV-16/18 vaccine (2 doses)
Study: 29424799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 dose of measles-mumps-rubella and diphtheria-tetanus-acellular-pertussis vaccines)
Study: 26666342
Drug: Procalcitonin ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin ≥ 0.20 ng/mL (N=104)
Study: 26666342
Drug: Procalcitonin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin < 0.20 ng/mL
Study: 24462855
Drug: Systemic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate (MTX) combined with ultrasound-guided local injection of potassium chloride (KCl) or MTX
Study: 20642545
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg (morning dosing)
Study: 20642545
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg (evening dosing)
Study: 20642545
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of Vildagliptin 100 mg
Study: 17715164
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100-125 ppm carbon monoxide (CO) for 2 hours per day over 4 consecutive days.
Study: 12065335
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI), 300 mg bid
Study: 12065335
Drug: Oral quinolone
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinolone antibiotics (primarily ciprofloxacin)
Study: 12065335
Drug: TSI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSI therapy
Study: 9537270
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (3 doses at 2, 3, and 4 months of age)
Study: 2523611
Drug: Goserelin (Zoladex),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (Zoladex), 3.6 mg sc/28 d
Study: 2523611
Drug: Diethylstilbestrol (DES),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES), 1 mg tid
Study: 904400
Drug: Challenge food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge food tests administered to patients.
Study: 31937553
Drug: Active respiratory
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active respiratory muscle training (RMT) performed twice daily for 6 weeks
Study: 29982701
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone) at adequate doses
Study: 28294136
Drug: morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (10 mg)
Study: 28294136
Drug: naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone (50 mg)
Study: 11249051
Drug: High-dose thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiotepa (600 mg/m2) + melphalan (160 mg/m2) with hemopoietic support
Study: 11249051
Drug: High-dose thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiotepa and melphalan
Study: 22850489
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBC) combined with physical therapy modalities and joint mobilization
Study: 22850489
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy modalities and passive joint mobilization of the shoulder (non-WBC group)
Study: 21118164
Drug: Ivabradine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine added to standard therapy
Study: 21118164
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of SA and CHF
Study: 10960460
Drug: Triple antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiviral therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily, amantadine 200 mg daily) for 12 months
Study: 10960460
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily) for 12 months
Study: 10960460
Drug: Triple antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiviral therapy
Study: 6342543
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment together with intrathecal equine antitetanus serum
Study: 6342543
Drug: Parenteral intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral intramuscular diazepam as a sedative
Study: 6342543
Drug: Paraldehyde as
Normalized name: Paraldehyde
DrugBank: Paraldehyde (DB09117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraldehyde as a sedative
Study: 25169631
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg, tid
Study: 25169631
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (low‐flow oxygen, low‐salt diet therapy, cardiac therapy)
Study: 16820805
Drug: HydraBrush Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HydraBrush Oral Health System (OHS)
Study: 10937603
Drug: Pharmacotherapy (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (fluoxetine or bupropion)
Study: 6840904
Drug: Drug-free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free period
Study: 30700278
Drug: Song of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Song of Life (SOL) music therapy
Study: 22453248
Drug: oral glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral glycerol = sports drink, water, and glycerol
Study: 22453248
Drug: IV with
Normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV with oral glycerol = half as normal saline, half as sports drink, water, and glycerol
Study: 22453248
Drug: oral =
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral = sports drink and water
Study: 20400004
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO(4)) infusion
Study: 17511361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sandblasting with tribochemical silica coating
Study: 17511361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sandblasting and tribochemical silica coating
Study: 12162381
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO2) - 40 sessions over 2 months, 1 hour exposure to 100% oxygen at 1.75 ATA
Study: 12162381
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 40 sessions over 2 months, 1 hour exposure to air at 1.3 ATA
Study: 30306805
Drug: Neurodynamic techniques
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamic techniques (20 sessions, twice weekly)
Study: 19546818
Drug: Gemcitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m2 in 20 to 30 minutes) + Cisplatin (75 mg/m2 on day 2)
Study: 19546818
Drug: Gemcitabine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2)
Study: 19546818
Drug: Gemcitabine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2) in patients with squamous carcinoma
Study: 15193818
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + Simvastatin 20 mg daily
Study: 11463131
Drug: Chewing dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing dextrose tablets
Study: 9874905
Drug: High‐intensity, socially
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐intensity, socially demanding day treatment program (DTP)
Study: 7978377
Drug: Sperm preparation
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sperm preparation using immunobeads
Study: 2926575
Drug: Spironolactone-hydrochlorothiazide (Aldactazide)
Normalized name: hydrochlorothiazide / spironolactone Oral Tablet [Aldactazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone-hydrochlorothiazide (Aldactazide) at 3 mg/kg/day for 6 to 8 days (n = 12)
Study: 2926575
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 9)
Study: 4593554
Drug: Clonidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (25 to 75 mcg twice daily)
Study: 31397866
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (rotator cuff surgery followed by approximately 4 months of postoperative rehabilitation)
Study: 31397866
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (approximately 3‐month standardized physical therapy program)
Study: 28244415
Drug: Liquid honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid honey (10 mL, 4 times a day)
Study: 28244415
Drug: Lozenge honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge honey (10 mL, 4 times a day)
Study: 25529033
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of IGU and methotrexate
Study: 22812912
Drug: Protocol 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1: acid-etching (dentin) + silica coating (composite) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Study: 22812912
Drug: Protocol 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2: silica coating (composite) + acid-etching (dentin) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Study: 22812912
Drug: Protocol 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 3: acid-etching (dentin) + primer (dentin) + silanization (composite) + bonding agent (dentin + composite)
Study: 15660766
Drug: Zonisamide 300
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 300 mg/day
Study: 21166480
Drug: Zonisamide 400
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 400 mg/day
Study: 21166480
Drug: Zonisamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (300 and 400 mg/day)
Study: 18377143
Drug: Hypnotic taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic taper intervention with self-help treatment for insomnia
Study: 18377143
Drug: Hypnotic taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic taper intervention without self-help treatment for insomnia
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 1)
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 2)
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied once daily for 2 weeks (all cohorts)
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (all cohorts)
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied once daily for 2 weeks
Study: 17178982
Drug: 0.1% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks
Study: 10783018
Drug: Negative nasopharyngeal
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NT‐AOM
Study: 10783018
Drug: Negative nasopharyngeal
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NR‐AOM
Study: 1458764
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (20mg)
Study: 1458764
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole (40mg)
Study: 1458764
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral omeprazole
Study: 6327543
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 600 mg intramuscularly daily for 12 days
Study: 6327543
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg daily for 21 days
Study: 6327543
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sodium stibogluconate and rifampin
Study: 29804728
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to frontline therapy
Study: 24812022
Drug: Non-assigned treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-assigned treatments (pharmacotherapy, behavioral, alternative, non-study Internet)
Study: 20482243
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro pen
Study: 19018255
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of individual support and group rehabilitation
Study: 9690944
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of erythropoietin (Epoetin beta)
Study: 8080985
Drug: RGD peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGD peptide matrix treatment
Study: 8080985
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus RGD peptide matrix
Study: 2753986
Drug: Hydergine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine (2 mg, single oral dose)
Study: 2753986
Drug: Hydergine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine (2 mg, 3 times daily, chronic treatment for 4-12 weeks)
Study: 2753986
Drug: Hydergine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine (2 mg, 3 times daily, chronic treatment for 4-104 weeks)
Study: 29203842
Drug: Clomipramine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 15 mg/day
Study: 29203842
Drug: Clomipramine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 30 mg/day
Study: 23543311
Drug: Weekly PEG‐IFNα‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly PEG‐IFNα‐2a (group C)
Study: 23543311
Drug: Biweekly therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly therapy (group D)
Study: 20804630
Drug: Cranberry powder
Normalized name: Cranberry powder/extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry powder (1500 mg per day for 6 months)
Study: 20804630
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cranberry treatment)
Study: 14983613
Drug: Lipid clinic
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid clinic model intervention including diet, medication, and follow-up by nurses and physicians.
Study: 14983613
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice control group treatment by general internists.
Study: 1314147
Drug: Fragmin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (5000 IU subcutaneously once daily for six days)
Study: 2982534
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sodium bicarbonate
Study: 2982534
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ammonium chloride
Study: 30368584
Drug: H3B-6527 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3B-6527 (200 mg dose) after a high-fat meal
Study: 30368584
Drug: H3B-6527 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3B-6527 (200 mg dose) after fasting
Study: 29901710
Drug: Mediterranean Pattern
Normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean Pattern with 500 g lean, unprocessed red meat (Med-Red)
Study: 29901710
Drug: Mediterranean Pattern
Normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean Pattern with 200 g lean, unprocessed red meat (Med-Control)
Study: 22179735
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) 3 g daily
Study: 18807577
Drug: D-003 5
Normalized name: 5-HYDROXYTRYPTOPHAN, D-
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 5 mg/d
Study: 10421537
Drug: Chemoradiation (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (5000 cGy, Cisplatin 75 mg/m2, Fluorouracil 1000 mg/m2 for 4 days)
Study: 24108526
Drug: Esmolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (continuous infusion titrated to maintain heart rate between 80/min and 94/min)
Study: 15668416
Drug: Intraduodenal levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal levodopa/carbidopa infusion
Study: 15668416
Drug: Conventional combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combination therapies
Study: 12036647
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine 1%
Study: 12036647
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 4%